# Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Study · id `cardio:ct-nct01854918` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01854918](<https://clinicaltrials.gov/study/NCT01854918>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01854918

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3681 participants.

## Technical summary

Registry record NCT01854918. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2018-05-31 (actual). Results posted on 2019-06-11.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3681 participants (enrolled count; ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Started: 2013-04-23 (actual) (ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Primary completion: 2018-05-31 (actual) (ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Completion: 2018-05-31 (actual) (ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Results first posted: 2019-06-11 (ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Canada; Czechia; Denmark; France; Germany; Hong Kong SAR China; Hungary; Italy; Japan; Netherlands; New Zealand; Norway; Poland; Russia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01854918, source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01854918-2019-06-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
- Acronym: OSLER-2
- Condition: Hyperlipidemia and Mixed Dyslipidemia
- Intervention (Biological): Evolocumab
- Intervention (Drug): Standard of Care
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus (`cardio:pubmed-28844508`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia (`cardio:pubmed-29066265`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 35dc86fd66bc4a94bb127a42933b6bd9721ec9583f35155d33566963b59d17d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
